Base de dados : MEDLINE
Pesquisa : D03.383.663.283.446.794 [Categoria DeCS]
Referências encontradas : 2246 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 225 ir para página                         

  1 / 2246 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28448889
[Au] Autor:Yang A; Chen J; Ma Y; Wang L; Fan Y; He X
[Ad] Endereço:School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, PR China; Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin, 300193, PR China.
[Ti] Título:Studies on the metabolites difference of psoralen/isopsoralen in human and six mammalian liver microsomes in vitro by UHPLC-MS/MS.
[So] Source:J Pharm Biomed Anal;141:200-209, 2017 Jul 15.
[Is] ISSN:1873-264X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Psoralen and isopsoralen are found in many fruits, vegetables and traditional Chinese medicines (TCM), such as Ficus carica L., Celery, Fructus Psoraleae etc. Modern pharmacological studies found that psoralen and isopsoralen can show estrogen-like activity, antitumor, and antibacterial activities etc. However, some research results also show some liver damage associated with the use of psoralen/isopsoralen or related medicines in human. Many studies focus on the pharmacological activities of psoralen/isopsoralen, while it is important to choose the suitable pharmacological models which are relevant to human in drug metabolism and pharmacokinetic process. The aim of this study is to identify the metabolites of psoralen/isopsoralen by human and six mammalian liver microsomes, and compare the metabolites difference of different species. Psoralen/isopsoralen are metabolized by liver microsomes of different animals to form five and seven metabolites, respectively. The metabolism of psoralen/isopsoralen undergoes hydroxylation, hydrogenation and hydrolysis, and oxidation of the furan ring to generate a furanoepoxide or γ-ketoenal intermediate. Furanoepoxide then forms a dihydrodiol, while γ-ketoenal forms 6-(7-hydroxycoumaryl)-acetic acid (in psoralen)/8-(7-hydroxycoumaryl)-acetic acid (in isopsoralen). By comparing the types of metabolites in the seven liver microsomes, it shows that the metabolic behaviors of psoralen by Beagle dog is most relevant to human, while the metabolic behaviors of isopsoralen by Sprague-Dawley rat is most similar to human. By comparing the relative amounts of the main metabolites, it shows that the metabolic capabilities of Sprague-Dawley rat and Rhesus monkey for psoralen are most similar to human, while the metabolic capabilities of Mouse, Dunkin-Hartley guinea pig, Sprague-Dawley rat, and human for isopsoralen are similar. Furthermore, the results show that the metabolic capability of human for psoralen and isopsoralen are weaker than other mammal species. The results of this work are useful for studying the metabolism mechanism of psoralen/isopsolaren, and choosing the most relevant animal species for investigation of psoralen/isopsolaren from experimental animals to human.
[Mh] Termos MeSH primário: Microssomos Hepáticos
[Mh] Termos MeSH secundário: Animais
Cromatografia Líquida de Alta Pressão
Ficusina
Furocumarinas
Seres Humanos
Ratos Sprague-Dawley
Espectrometria de Massas em Tandem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Furocoumarins); CZZ080D7BD (angelicin); KTZ7ZCN2EX (Ficusin)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180125
[Lr] Data última revisão:
180125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170428
[St] Status:MEDLINE


  2 / 2246 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28872685
[Au] Autor:Tonnetti L; Laughhunn A; Thorp AM; Vasilyeva I; Dupuis K; Stassinopoulos A; Stramer SL
[Ad] Endereço:Scientific Affairs, American Red Cross Holland Laboratory, Rockville, Maryland.
[Ti] Título:Inactivation of Babesia microti in red blood cells and platelet concentrates.
[So] Source:Transfusion;57(10):2404-2412, 2017 Oct.
[Is] ISSN:1537-2995
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: With an increasing number of recognized transfusion-transmitted (TT) babesiosis cases, Babesia microti is the most frequently TT parasite in the United States. We evaluated the inactivation of B. microti in red blood cells (RBCs) prepared in Optisol (AS-5) using amustaline and glutathione (GSH) and in platelet components (PCs) in 100% plasma using amotosalen and low-energy ultraviolet A (UVA) light. STUDY DESIGN AND METHODS: Individual RBCs and apheresis PCs were spiked with B. microti-infected hamster RBCs (iRBCs) to a final concentration of 10 iRBCs/mL and treated with the respective inactivation systems according to the manufacturer's instruction. Samples were collected before (control) and after (test) each treatment. Dilutions of the control samples to 10 were inoculated into hamsters, while the test samples were inoculated neat or at 10 dilution. At 3 and 5 weeks postinoculation, hamsters were evaluated for B. microti infection by microscopic observation of blood smears and 50% infectivity titers (ID ) were determined. Log reduction was calculated as control log ID minus test log ID . RESULTS: Parasitemia was detected in hamsters injected with as low as 100,000-fold diluted control samples, while no parasites were detectable in the blood smears of any hamsters receiving neat test samples. Mean log reduction was more than 5 log/mL by amustaline/GSH for RBCs and more than 4.5 log/mL by amotosalen/UVA for PCs. CONCLUSION: B. microti was inactivated to the limit of detection in RBCs and PCs after the respective inactivation treatment. Complete inactivation of B. microti was achieved in this animal infectivity model, and pathogen reduction treatment inhibited transmission of infection.
[Mh] Termos MeSH primário: Babesia microti
Babesiose/transmissão
Plaquetas/parasitologia
Desinfecção/métodos
Eritrócitos/parasitologia
[Mh] Termos MeSH secundário: Animais
Babesiose/prevenção & controle
Cricetinae
Furocumarinas
Glutationa
Raios Ultravioleta
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Furocoumarins); GAN16C9B8O (Glutathione); K1LDZ0VBC0 (amotosalen)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170906
[St] Status:MEDLINE
[do] DOI:10.1111/trf.14280


  3 / 2246 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28766723
[Au] Autor:Saadah NH; van Hout FMA; Schipperus MR; le Cessie S; Middelburg RA; Wiersum-Osselton JC; van der Bom JG
[Ad] Endereço:Center for Clinical Transfusion Research, Sanquin Blood Supply.
[Ti] Título:Comparing transfusion reaction rates for various plasma types: a systematic review and meta-analysis/regression.
[So] Source:Transfusion;57(9):2104-2114, 2017 Sep.
[Is] ISSN:1537-2995
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: We estimated rates for common plasma-associated transfusion reactions and compared reported rates for various plasma types. STUDY DESIGN AND METHODS: We performed a systematic review and meta-analysis of peer-reviewed articles that reported plasma transfusion reaction rates. Random-effects pooled rates were calculated and compared between plasma types. Meta-regression was used to compare various plasma types with regard to their reported plasma transfusion reaction rates. RESULTS: Forty-eight studies reported transfusion reaction rates for fresh-frozen plasma (FFP; mixed-sex and male-only), amotosalen INTERCEPT FFP, methylene blue-treated FFP, and solvent/detergent-treated pooled plasma. Random-effects pooled average rates for FFP were: allergic reactions, 92/10 units transfused (95% confidence interval [CI], 46-184/10 units transfused); febrile nonhemolytic transfusion reactions (FNHTRs), 12/10 units transfused (95% CI, 7-22/10 units transfused); transfusion-associated circulatory overload (TACO), 6/10 units transfused (95% CI, 1-30/10 units transfused); transfusion-related acute lung injury (TRALI), 1.8/10 units transfused (95% CI, 1.2-2.7/10 units transfused); and anaphylactic reactions, 0.8/10 units transfused (95% CI, 0-45.7/10 units transfused). Risk differences between plasma types were not significant for allergic reactions, TACO, or anaphylactic reactions. Methylene blue-treated FFP led to fewer FNHTRs than FFP (risk difference = -15.3 FNHTRs/10 units transfused; 95% CI, -24.7 to -7.1 reactions/10 units transfused); and male-only FFP led to fewer cases of TRALI than mixed-sex FFP (risk difference = -0.74 TRALI/10 units transfused; 95% CI, -2.42 to -0.42 injuries/10 units transfused). CONCLUSION: Meta-regression demonstrates that the rate of FNHTRs is lower for methylene blue-treated compared with FFP, and the rate of TRALI is lower for male-only than for mixed-sex FFP; whereas no significant differences are observed between plasma types for allergic reactions, TACO, or anaphylactic reactions. Reported transfusion reaction rates suffer from high heterogeneity.
[Mh] Termos MeSH primário: Plasma/química
Reação Transfusional
[Mh] Termos MeSH secundário: Detergentes
Feminino
Furocumarinas
Seres Humanos
Cinética
Masculino
Azul de Metileno
Fatores Sexuais
Solventes
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Detergents); 0 (Furocoumarins); 0 (Solvents); K1LDZ0VBC0 (amotosalen); T42P99266K (Methylene Blue)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171027
[Lr] Data última revisão:
171027
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170803
[St] Status:MEDLINE
[do] DOI:10.1111/trf.14245


  4 / 2246 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:28756627
[Au] Autor:Estcourt LJ; Malouf R; Hopewell S; Trivella M; Doree C; Stanworth SJ; Murphy MF
[Ad] Endereço:Haematology/Transfusion Medicine, NHS Blood and Transplant, Level 2, John Radcliffe Hospital, Headington, Oxford, UK, OX3 9BQ.
[Ti] Título:Pathogen-reduced platelets for the prevention of bleeding.
[So] Source:Cochrane Database Syst Rev;7:CD009072, 2017 07 30.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Platelet transfusions are used to prevent and treat bleeding in people who are thrombocytopenic. Despite improvements in donor screening and laboratory testing, a small risk of viral, bacterial, or protozoal contamination of platelets remains. There is also an ongoing risk from newly emerging blood transfusion-transmitted infections for which laboratory tests may not be available at the time of initial outbreak.One solution to reduce the risk of blood transfusion-transmitted infections from platelet transfusion is photochemical pathogen reduction, in which pathogens are either inactivated or significantly depleted in number, thereby reducing the chance of transmission. This process might offer additional benefits, including platelet shelf-life extension, and negate the requirement for gamma-irradiation of platelets. Although current pathogen-reduction technologies have been proven to reduce pathogen load in platelet concentrates, a number of published clinical studies have raised concerns about the effectiveness of pathogen-reduced platelets for post-transfusion platelet count recovery and the prevention of bleeding when compared with standard platelets.This is an update of a Cochrane review first published in 2013. OBJECTIVES: To assess the effectiveness of pathogen-reduced platelets for the prevention of bleeding in people of any age requiring platelet transfusions. SEARCH METHODS: We searched for randomised controlled trials (RCTs) in the Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane Library 2016, Issue 9), MEDLINE (from 1946), Embase (from 1974), CINAHL (from 1937), the Transfusion Evidence Library (from 1950), and ongoing trial databases to 24 October 2016. SELECTION CRITERIA: We included RCTs comparing the transfusion of pathogen-reduced platelets with standard platelets, or comparing different types of pathogen-reduced platelets. DATA COLLECTION AND ANALYSIS: We used the standard methodological procedures expected by Cochrane. MAIN RESULTS: We identified five new trials in this update of the review. A total of 15 trials were eligible for inclusion in this review, 12 completed trials (2075 participants) and three ongoing trials. Ten of the 12 completed trials were included in the original review. We did not identify any RCTs comparing the transfusion of one type of pathogen-reduced platelets with another.Nine trials compared Intercept® pathogen-reduced platelets to standard platelets, two trials compared Mirasol® pathogen-reduced platelets to standard platelets; and one trial compared both pathogen-reduced platelets types to standard platelets. Three RCTs were randomised cross-over trials, and nine were parallel-group trials. Of the 2075 participants enrolled in the trials, 1981 participants received at least one platelet transfusion (1662 participants in Intercept® platelet trials and 319 in Mirasol® platelet trials).One trial included children requiring cardiac surgery (16 participants) or adults requiring a liver transplant (28 participants). All of the other participants were thrombocytopenic individuals who had a haematological or oncological diagnosis. Eight trials included only adults.Four of the included studies were at low risk of bias in every domain, while the remaining eight included studies had some threats to validity.Overall, the quality of the evidence was low to high across different outcomes according to GRADE methodology.We are very uncertain as to whether pathogen-reduced platelets increase the risk of any bleeding (World Health Organization (WHO) Grade 1 to 4) (5 trials, 1085 participants; fixed-effect risk ratio (RR) 1.09, 95% confidence interval (CI) 1.02 to 1.15; I = 59%, random-effect RR 1.14, 95% CI 0.93 to 1.38; I = 59%; low-quality evidence).There was no evidence of a difference between pathogen-reduced platelets and standard platelets in the incidence of clinically significant bleeding complications (WHO Grade 2 or higher) (5 trials, 1392 participants; RR 1.10, 95% CI 0.97 to 1.25; I = 0%; moderate-quality evidence), and there is probably no difference in the risk of developing severe bleeding (WHO Grade 3 or higher) (6 trials, 1495 participants; RR 1.24, 95% CI 0.76 to 2.02; I = 32%; moderate-quality evidence).There is probably no difference between pathogen-reduced platelets and standard platelets in the incidence of all-cause mortality at 4 to 12 weeks (6 trials, 1509 participants; RR 0.81, 95% CI 0.50 to 1.29; I = 26%; moderate-quality evidence).There is probably no difference between pathogen-reduced platelets and standard platelets in the incidence of serious adverse events (7 trials, 1340 participants; RR 1.09, 95% CI 0.88 to 1.35; I = 0%; moderate-quality evidence). However, no bacterial transfusion-transmitted infections occurred in the six trials that reported this outcome.Participants who received pathogen-reduced platelet transfusions had an increased risk of developing platelet refractoriness (7 trials, 1525 participants; RR 2.94, 95% CI 2.08 to 4.16; I = 0%; high-quality evidence), though the definition of platelet refractoriness differed between trials.Participants who received pathogen-reduced platelet transfusions required more platelet transfusions (6 trials, 1509 participants; mean difference (MD) 1.23, 95% CI 0.86 to 1.61; I = 27%; high-quality evidence), and there was probably a shorter time interval between transfusions (6 trials, 1489 participants; MD -0.42, 95% CI -0.53 to -0.32; I = 29%; moderate-quality evidence). Participants who received pathogen-reduced platelet transfusions had a lower 24-hour corrected-count increment (7 trials, 1681 participants; MD -3.02, 95% CI -3.57 to -2.48; I = 15%; high-quality evidence).None of the studies reported quality of life.We did not evaluate any economic outcomes.There was evidence of subgroup differences in multiple transfusion trials between the two pathogen-reduced platelet technologies assessed in this review (Intercept® and Mirasol®) for all-cause mortality and the interval between platelet transfusions (favouring Intercept®). AUTHORS' CONCLUSIONS: Findings from this review were based on 12 trials, and of the 1981 participants who received a platelet transfusion only 44 did not have a haematological or oncological diagnosis.In people with haematological or oncological disorders who are thrombocytopenic due to their disease or its treatment, we found high-quality evidence that pathogen-reduced platelet transfusions increase the risk of platelet refractoriness and the platelet transfusion requirement. We found moderate-quality evidence that pathogen-reduced platelet transfusions do not affect all-cause mortality, the risk of clinically significant or severe bleeding, or the risk of a serious adverse event. There was insufficient evidence for people with other diagnoses.All three ongoing trials are in adults (planned recruitment 1375 participants) with a haematological or oncological diagnosis.
[Mh] Termos MeSH primário: Antissepsia/métodos
Plaquetas/microbiologia
Transmissão de Doença Infecciosa/prevenção & controle
Hemorragia/prevenção & controle
Transfusão de Plaquetas
Trombocitopenia/terapia
[Mh] Termos MeSH secundário: Adulto
Criança
Furocumarinas
Hemorragia/epidemiologia
Seres Humanos
Fármacos Fotossensibilizantes
Ensaios Clínicos Controlados Aleatórios como Assunto
Riboflavina
Raios Ultravioleta
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Furocoumarins); 0 (Photosensitizing Agents); K1LDZ0VBC0 (amotosalen); TLM2976OFR (Riboflavin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170912
[Lr] Data última revisão:
170912
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170731
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD009072.pub3


  5 / 2246 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28671343
[Au] Autor:Santa Maria F; Laughhunn A; Lanteri MC; Aubry M; Musso D; Stassinopoulos A
[Ad] Endereço:Cerus Corporation, Concord, California.
[Ti] Título:Inactivation of Zika virus in platelet components using amotosalen and ultraviolet A illumination.
[So] Source:Transfusion;57(8):2016-2025, 2017 Aug.
[Is] ISSN:1537-2995
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Concerned over the risk of Zika virus (ZIKV) transfusion transmission, public health agencies recommended the implementation of mitigation strategies for its prevention. Those strategies included the use of pathogen inactivation for the treatment of plasma and platelets. The efficacy of amotosalen/ultraviolet A to inactivate ZIKV in plasma had been previously demonstrated, and the efficacy of inactivation in platelets with the same technology was assumed. These studies quantify ZIKV inactivation in platelet components using amotosalen/ultraviolet A. STUDY DESIGN AND METHODS: Platelet components were spiked with ZIKV, and ZIKV infectious titers and RNA loads were measured by cell culture-based assays and real-time polymerase chain reaction in spiked platelet components before and after photochemical treatment using amotosalen/ultraviolet A. RESULTS: The mean ZIKV infectivity titers and RNA loads in platelet components before inactivation were either 4.9 log plaque forming units per milliliter, or 4.4 log 50% tissue culture infective dose per milliliter and 7.5 log genome equivalents per milliliter, respectively. No infectivity was detected immediately after amotosalen/ultraviolet A treatment. No replicative virus remained after treatment, as demonstrated by multiple passages on Vero cell cultures; and ZIKV RNA was not detected from the first passage after inactivation. Additional experiments in this study demonstrated efficient inactivation to the limit of detection in platelets manufactured in 65% platelet additive solution, 35% plasma, or 100% plasma. CONCLUSION: As previously demonstrated for plasma, robust levels of ZIKV inactivation were achieved in platelet components. With inactivation of higher levels of ZIKV than those reported in asymptomatic, RNA-reactive blood donors, the pathogen-inactivation system using amotosalen/ultraviolet A offers the potential to mitigate the risk of ZIKV transmission by plasma and platelet transfusion.
[Mh] Termos MeSH primário: Plaquetas/virologia
Furocumarinas/farmacologia
Raios Ultravioleta
Inativação de Vírus
Zika virus
[Mh] Termos MeSH secundário: Animais
Cercopithecus aethiops
Seres Humanos
Transfusão de Plaquetas/efeitos adversos
RNA Viral
Células Vero
Carga Viral
Inativação de Vírus/efeitos dos fármacos
Inativação de Vírus/efeitos da radiação
Zika virus/efeitos dos fármacos
Zika virus/efeitos da radiação
Infecção pelo Zika virus/prevenção & controle
Infecção pelo Zika virus/transmissão
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Furocoumarins); 0 (RNA, Viral); K1LDZ0VBC0 (amotosalen)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170704
[St] Status:MEDLINE
[do] DOI:10.1111/trf.14161


  6 / 2246 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28581738
[Au] Autor:Melough MM; Lee SG; Cho E; Kim K; Provatas AA; Perkins C; Park MK; Qureshi A; Chun OK
[Ad] Endereço:Department of Nutritional Sciences, University of Connecticut , Storrs, Connecticut 06269, United States.
[Ti] Título:Identification and Quantitation of Furocoumarins in Popularly Consumed Foods in the U.S. Using QuEChERS Extraction Coupled with UPLC-MS/MS Analysis.
[So] Source:J Agric Food Chem;65(24):5049-5055, 2017 Jun 21.
[Is] ISSN:1520-5118
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Furocoumarins are a class of photoactive compounds found in several plant species and may be responsible for the observed association between consumption of citrus products and the risk of skin cancer. Furocoumarin contents of several foods have been reported previously, but no comprehensive database of furocoumarin content of foods is currently available. Therefore, this study aimed to determine the distribution of furocoumarins in popularly consumed foods in the U.S. Samples of three varieties of each of 29 foods known or suspected to contain furocoumarins were purchased, prepared for analysis using a solid phase extraction method, and analyzed using UPLC-MS/MS for the presence of seven major furocoumarins. Most foods measured contained more than one furocoumarin, and some contained all seven of the furocoumarins examined. Total furocoumarin concentration was greatest in fresh parsley (23215 ng/g), grapefruits (21858 ng/g), lime juice (14580 ng/g), grapefruit juice (95341 ng/g), and limes (9151 ng/g). Bergamottin was found in the greatest proportion of foods sampled (23 of 29), followed by bergapten (19 of 29) and 6'7'-dihydroxybergamottin (16 of 29). These measurements will enable more accurate estimation of dietary furocoumarin exposure and will strengthen future epidemiological work investigating the relationships between furocoumarin intake and health outcomes.
[Mh] Termos MeSH primário: Sucos de Frutas e Vegetais/análise
Frutas/química
Furocumarinas/química
Furocumarinas/isolamento & purificação
Extratos Vegetais/química
Extratos Vegetais/isolamento & purificação
Verduras/química
[Mh] Termos MeSH secundário: Cromatografia Líquida de Alta Pressão/métodos
Análise de Alimentos
Seres Humanos
Extração em Fase Sólida/métodos
Espectrometria de Massas em Tandem/métodos
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Furocoumarins); 0 (Plant Extracts)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170703
[Lr] Data última revisão:
170703
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170606
[St] Status:MEDLINE
[do] DOI:10.1021/acs.jafc.7b01279


  7 / 2246 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28566583
[Au] Autor:Mizuno H; Hatano T; Taketomi A; Kawabata M; Nakabayashi T
[Ad] Endereço:School of Pharmaceutical Sciences, Mukogawa Women's University.
[Ti] Título:Bergamottin Promotes Adipocyte Differentiation and Inhibits Tumor Necrosis Factor-α-induced Inflammatory Cytokines Induction in 3T3-L1 Cells.
[So] Source:Yakugaku Zasshi;137(6):775-781, 2017.
[Is] ISSN:1347-5231
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:Nowadays, a lot of food ingredients are marketed as dietary supplements for health. Because the effectiveness and mechanisms of these compounds have not been fully characterized, they might have unknown functions. Therefore, we investigated the effect of several food ingredients (Bergamottin, Chrysin, L-Citrulline and ß-Carotene) known as health foods on adipocyte differentiation by using 3T3-L1 preadipocytes. In this study, we found that Bergamottin, a furanocoumarin isolated from grapefruit juice, promotes adipocyte differentiation. In addition, Bergamottin increases the expression of adiponectin, an anti-inflammatory adipokine, and peroxisome proliferator activated receptor γ (PPARγ), a nuclear receptor regulating adipocyte differentiation. Furthermore, the anti-inflammatory activity of Bergamottin was demonstrated by its inhibition of the activation of nuclear factor-κB (NF-κB), an inflammatory transcription factor. Stimulation of mature 3T3-L1 adipocytes by tumor necrosis factor-α (TNF-α) decreased the expression of the endogeneous NF-κB inhibitor, IκBα. Treatment with Bergamottin further decreased the TNF-α-induced change in IκBα expression, suggesting that Bergamottin mediated the inhibition of NF-κB activation. In addition, Bergamottin decreased the TNF-α-induced increase in the mRNA levels of pro-inflammatory adipokines, monocyte chemoattractant protein-1 and interleukin-6. Taken together, our results show that Bergamottin treatment could inhibit inflammatory activity through promoting adipocyte differentiation, which in turn suggests that Bergamottin has the potential to minimize the risk factors of metabolic syndrome.
[Mh] Termos MeSH primário: Adipócitos/citologia
Adipócitos/metabolismo
Diferenciação Celular/efeitos dos fármacos
Citocinas/metabolismo
Furocumarinas/farmacologia
Mediadores da Inflamação/metabolismo
Fator de Necrose Tumoral alfa/efeitos adversos
[Mh] Termos MeSH secundário: Células 3T3-L1
Adipocinas/metabolismo
Adiponectina/metabolismo
Animais
Citrus paradisi/química
Suplementos Nutricionais
Furocumarinas/isolamento & purificação
Furocumarinas/uso terapêutico
Síndrome Metabólica/prevenção & controle
Camundongos
NF-kappa B/metabolismo
PPAR gama/metabolismo
Fitoterapia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adipokines); 0 (Adiponectin); 0 (Cytokines); 0 (Furocoumarins); 0 (Inflammation Mediators); 0 (NF-kappa B); 0 (PPAR gamma); 0 (Tumor Necrosis Factor-alpha); JMU611YFRB (bergamottin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170602
[St] Status:MEDLINE
[do] DOI:10.1248/yakushi.16-00269


  8 / 2246 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28285927
[Au] Autor:Uruma Y; Nonomura T; Yen PY; Edatani M; Yamamoto R; Onuma K; Okada F
[Ad] Endereço:Department of Materials Science, National Institute of Technology, Yonago College, Yonago City, Tottori 683-8502, Japan. Electronic address: uruma@yonago-k.ac.jp.
[Ti] Título:Design, synthesis, and biological evaluation of a highly water-soluble psoralen-based photosensitizer.
[So] Source:Bioorg Med Chem;25(8):2372-2377, 2017 Apr 15.
[Is] ISSN:1464-3391
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:In recent years, photodynamic therapy (PDT) has been approved for treating various medical conditions, including cancer. PDT is a treatment that employs a particular drugs, called photosensitizers which work along with specific light source. The growth of this medical industry is expanding as it is another promising alternative to treat cancer which lessen the burden of treatments in patients. This includes the benefits of minimally invasive procedures and delivering high accuracy in targeting mutations. In recent two decades, cancer researchers have produced remarkable studies on developing photosensitizers that enhance understanding of biology and genetics of cancer. It is unfortunate that not all PDT can work as well as other profound treatment because PDT has various limitations like PDT leads photosensitivity reaction that arises when the photosensitizer remains in the body for a long period of time. In this paper, our studies centers on synthesizing a highly soluble photosensitizing agent with improved effectiveness on detecting cancer cells.
[Mh] Termos MeSH primário: Furocumarinas/química
Furocumarinas/farmacologia
Fármacos Fotossensibilizantes/química
Fármacos Fotossensibilizantes/farmacologia
Água/química
[Mh] Termos MeSH secundário: Células 3T3
Animais
Espectroscopia de Ressonância Magnética Nuclear de Carbono-13
Desenho de Drogas
Furocumarinas/síntese química
Camundongos
Camundongos Endogâmicos BALB C
Fotoquimioterapia
Fármacos Fotossensibilizantes/síntese química
Espectroscopia de Prótons por Ressonância Magnética
Solubilidade
Espectrometria de Massas de Bombardeamento Rápido de Átomos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Furocoumarins); 0 (Photosensitizing Agents); 059QF0KO0R (Water)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170907
[Lr] Data última revisão:
170907
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170314
[St] Status:MEDLINE


  9 / 2246 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28272365
[Au] Autor:Hwang YH; Yang HJ; Ma JY
[Ad] Endereço:KM Application Center, Korea Institute of Oriental Medicine, Daegu 41062, Korea. hyhhwang@kiom.re.kr.
[Ti] Título:Simultaneous Determination of Three Furanocoumarins by UPLC/MS/MS: Application to Pharmacokinetic Study of Angelica dahurica Radix after Oral Administration to Normal and Experimental Colitis-Induced Rats.
[So] Source:Molecules;22(3), 2017 Mar 07.
[Is] ISSN:1420-3049
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:In traditional oriental medicine, Radix (ADR) is used in the treatment of gastrointestinal, respiratory, neuromuscular, and dermal disorders. We evaluated the pharmacokinetic profiles of oxypeucedanin, imperatorin, and isoimperatorin, major active ingredients of ADR, in normal and 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis rats. A rapid, sensitive, and validated UPLC/MS/MS method was established for evaluating the pharmacokinetics of three furanocoumarins. After oral administration of ADR (0.5 and 1.0 g/kg), blood samples were collected periodically from the tail vein. In colitis rats, the time to reach the peak concentration (T ) of imperatorin and isoimperatorin was significantly delayed ( < 0.05). Lower peak plasma concentrations (C ) and longer mean residence times for all furanocoumarins were also observed ( < 0.05) compared with normal rats. There was no significant difference in the area under the plasma concentration-time curve or elimination half-lives. Thus, the delayed T and decreased C , with no influence on the elimination half-life, could be colitis-related changes in the drug-absorption phase. Therefore, the prescription and use of ADR in colitis patients should receive more attention.
[Mh] Termos MeSH primário: Colite/patologia
Furocumarinas/química
Furocumarinas/farmacocinética
[Mh] Termos MeSH secundário: Angelica/química
Animais
Cromatografia Líquida de Alta Pressão
Colite/tratamento farmacológico
Colite/etiologia
Modelos Animais de Doenças
Estabilidade de Medicamentos
Furocumarinas/administração & dosagem
Masculino
Estrutura Molecular
Extratos Vegetais/administração & dosagem
Extratos Vegetais/química
Extratos Vegetais/farmacocinética
Ratos
Reprodutibilidade dos Testes
Espectrometria de Massas em Tandem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Furocoumarins); 0 (Plant Extracts)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170518
[Lr] Data última revisão:
170518
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170309
[St] Status:MEDLINE


  10 / 2246 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28262582
[Au] Autor:Yang Z; Nejad MI; Varela JG; Price NE; Wang Y; Gates KS
[Ad] Endereço:University of Missouri Department of Chemistry, 125 Chemistry Building Columbia, MO 65211, United States.
[Ti] Título:A role for the base excision repair enzyme NEIL3 in replication-dependent repair of interstrand DNA cross-links derived from psoralen and abasic sites.
[So] Source:DNA Repair (Amst);52:1-11, 2017 Apr.
[Is] ISSN:1568-7856
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Interstrand DNA-DNA cross-links are highly toxic lesions that are important in medicinal chemistry, toxicology, and endogenous biology. In current models of replication-dependent repair, stalling of a replication fork activates the Fanconi anemia pathway and cross-links are "unhooked" by the action of structure-specific endonucleases such as XPF-ERCC1 that make incisions flanking the cross-link. This process generates a double-strand break, which must be subsequently repaired by homologous recombination. Recent work provided evidence for a new, incision-independent unhooking mechanism involving intrusion of a base excision repair (BER) enzyme, NEIL3, into the world of cross-link repair. The evidence suggests that the glycosylase action of NEIL3 unhooks interstrand cross-links derived from an abasic site or the psoralen derivative trioxsalen. If the incision-independent NEIL3 pathway is blocked, repair reverts to the incision-dependent route. In light of the new model invoking participation of NEIL3 in cross-link repair, we consider the possibility that various BER glycosylases or other DNA-processing enzymes might participate in the unhooking of chemically diverse interstrand DNA cross-links.
[Mh] Termos MeSH primário: Adutos de DNA/metabolismo
Dano ao DNA
Reparo do DNA
Furocumarinas/metabolismo
N-Glicosil Hidrolases/metabolismo
[Mh] Termos MeSH secundário: Animais
Reagentes para Ligações Cruzadas/toxicidade
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Cross-Linking Reagents); 0 (DNA Adducts); 0 (Furocoumarins); 0 (psoralen-DNA adduct); EC 3.2.2.- (FLJ10858 protein, human); EC 3.2.2.- (N-Glycosyl Hydrolases)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170916
[Lr] Data última revisão:
170916
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170307
[St] Status:MEDLINE



página 1 de 225 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde